Saniona: Robust phase III data from Viking study (tesofensine)
Research Note
2018-12-17
15:46
Saniona announced today that tesofensine met its primary and secondary endpoints in the phase III trial in obesity patients. The results demonstrated a statistically and clinically significant weight loss in obesity patients.
AH
Anders Hedlund
Disclosures and disclaimers